ImmunoCellular Therapeutics, Ltd and BioWa Announce License for the Research and Development of Therapeutic Antibodies in Cancer

ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) and BioWa, Inc. (BioWa) today announced that they have entered into a agreement to provide IMUC with access to BioWa’s patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. Under the agreement Biowa will receive the right to certain antibody technology from IMUC and selected option rights to IMUC antibodies using the POTELLIGENT® Technology.